Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 901–1,000 of 1,000
Descriptive Symbolic Models of Gaits from Parkinson's Disease Patients
Hughes, J. A., Houghten, S. K., & Brown, J. A. (2019) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb.2019.8791459 · Cited by 8
“Roughly 1% of the population over the age of 60 and 3% over the age of 80 have PD [16].”
BackgroundEditorial: Integrative Approach to Parkinson's Disease
Kim, S., Wang, X., & Park, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00339 · Cited by 8
“Emerging evidence indicates that PD is currently the second most common neurological disorder, with a prevalence of ∼1% among individuals aged 60–70 years, increasing to ∼3% among those aged 80 years and older (Tanner and Goldman, 1996; Nussbaum and Ellis, 2003).”
BackgroundSarmiento, R. M. R., Berchtold, S., Manevski, N., Lindemann, L., Dey, F., Clairfeuille, T., Amendola, D., Vautrelle, N., Duveau, V., & O’Connor, E. C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00294 · Cited by 7
de Mello-Sampayo, C., Pádua, M. S., Silva, M. R., Lourenço, M. E. M., Pinto, R. M. A., Carvalho, S., Correia, J., Martins, C. F., Gomes, R., Gomes‐Bispo, A., et al. (2025) · Biomolecules · doi:10.3390/biom15081164 · Cited by 7
“…[11,12] with β -amyloid plaque deposition and neurofibrillary tangles, turning these features into the pathophysiological hallmarks of AD [11,13,14]. β -amyloid plaques are the result of this peptide oligomer accumulation, triggered by a disrupted cleavage of the amyloid precursor…”
Ye, M., Kang, X., Karlsson, I., Wang, Y., Ji, Q., Liu, Q., Xu, X., Hägg, S., Fang, F., Wirdefeldt, K., et al. (2024) · Neuroepidemiology · doi:10.1159/000536555 · Cited by 7
Khan, S. A., & Haider, M. F. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273323074241001071645 · Cited by 7
Kim, D. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14060597 · Cited by 9
Long-term administration of excess zinc impairs learning and memory in aged mice
Yoshida, K., Gi, M., Fujioka, M., Teramoto, I., & Wanibuchi, H. (2019) · The Journal of Toxicological Sciences · doi:10.2131/jts.44.681 · Cited by 9
Molecular signatures in exosomes as diagnostic markers for neurodegenerative disorders
Palaniswamy, R., Sevugan, K., & Srisharnitha, A. S. (2020) · Annals of Alzheimer s and Dementia Care · doi:10.17352/aadc.000012 · Cited by 7
Gai, C., Qiang, T., Zhang, Y., Chai, Y., Feng, W.-D., & Sun, H. (2021) · Medicine · doi:10.1097/md.0000000000023010 · Cited by 7
Mathioudakis, L., Dimovasili, C., Bourbouli, M., Latsoudis, H., Kokosali, E., Gouna, G., Vogiatzi, E., Basta, M., Kapetanaki, S., Panagiotakis, S., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.002 · Cited by 7
Use of invertebrates to model chemically induced parkinsonism-symptoms
Corrêa, C. L., Gomes, C. A. B. D. A., Mello, A. D. A., Nogueira, N. D. S., Medeiros, T. B., de Barros, C. M., & Allodi, S. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221172 · Cited by 7
Applications of 3D printing in aging
Ma, M., Gu, J., Wang, D., Bi, S., Liu, R., Zhang, X., Yang, J. Y., & Zhang, Y. (2024) · International Journal of Bioprinting · doi:10.18063/ijb.732 · Cited by 7
Family History of AD /Dementia, Polygenic Risk Score for AD , and Parkinson's Disease
Xu, X., Li, Y., Wang, J., Cao, Y., Feng, C., Guo, Y. H., Zong, G., Sun, L., & Gao, X. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13919 · Cited by 7
Minor retinal degeneration in Parkinson’s disease
Huang, Y. M., & Yin, Z. Q. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.09.016 · Cited by 7
“The progressive loss of dopaminergic neurons in substantia nigra in PD is due to a complex interaction among multiple predisposing genes and environmental contributions [3].”
BackgroundAltered β‐Amyloid Precursor Protein Isoforms in Mexican Alzheimer’s Disease Patients
Sánchez-González, V., Ortíz, G. G., Gallegos-Arreola, P., Macías-Islas, M. Á., Arias‐Merino, E. D., Loera‐Castañeda, V., Martínez-Cano, E., Velázquez-Brizuela, I. E., Rosales‐Corral, S., Curiel-Ortega, C. R., et al. (2006) · Disease Markers · doi:10.1155/2006/347502 · Cited by 10
Linking atherosclerosis to Alzheimer's disease: focus on biomarkers
Emanuele, E. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/411 · Cited by 7
New horizons in the pathogenesis, assessment and management of movement disorders
Duncan, G. W., Yarnall, A. J., Marrinan, S. L., & Burn, D. J. (2012) · Age and Ageing · doi:10.1093/ageing/afs103 · Cited by 8
The Molecular, Biochemical, and Cellular Basis of Genetic Disease
Nussbaum, R. L., McInnes, R. R., Willard, H. F., & Hamosh, A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3080-5.50015-8 · Cited by 7
Self-citationKim, J. Y., Son, M. J., Kim, Y. K., Lee, M. G., Kim, J. H., & Youm, C. (2016) · Korean Journal of Sport Biomechanics · doi:10.5103/kjsb.2016.26.3.293 · Cited by 7
“The prevalence increases to 1% among the elderly population aged 60 years or older (Nussbaum & Ellis, 2003; de Lau & Breteler, 2006), with an annual incidence of 8~18 cases per 100,000 (de Lau & Breteler, 2006; Kim, Kim, & Lim, 2015).”
BackgroundEvangelista, B., Kim, Y., & Kolpashchikov, D. M. (2018) · ChemBioChem · doi:10.1002/cbic.201800017 · Cited by 7
The relationship between the minor allele content and Alzheimer's disease
Chen, H., Lei, X., Yuan, D., & Huang, S. (2020) · Genomics · doi:10.1016/j.ygeno.2020.01.015 · Cited by 7
Managing Advanced Parkinson Disease
Hwang, H., & Norris, S. A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211018277 · Cited by 8
Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein
Ganguly, U., Singh, S., Chakrabarti, S., Saini, A. K., & Saini, R. V. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2021.11.010 · Cited by 7
Zou, X., Xu, M., Dong, X., Ying, Y., Guan, R., Wu, W., Yang, K., & Sun, P. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14208 · Cited by 7
Repurposing of Kinase Inhibitors to Target c-Abl as Potential Therapeutics for Alzheimer’s Disease
Zhu, Q., Chen, J., Wu, X. L., Jin, X., & Ruan, B. (2014) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-014-9202-5 · Cited by 7
“As the most common neurodegenerative disease, AD constitutes about two thirds of cases of dementia overall, with vascular causes and other neurodegenerative diseases such as Pick’s disease and diffuse Lewy-body dementia making up the majority of the remaining cases [1].”
Kosa, A., Lopez‐Gutierrez, L., Ando, K., Doeraene, E., Aydin, E., Lasri, H., Wathelet‐Depauw, A., Pieters, K., Morckhoven, D. V., Imbault, V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70784 · Cited by 6
Alharbi, L. I., Badr, E. M., Donia, A., & Monir, E. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47120976 · Cited by 10
“PD prevalence increases with age, affecting approximately 1% of individuals over 60 years [12,13], and is expected to rise by more than 30% by 2030 due to global population aging [14].”
Liu, Y., Chen, Y., & Fukui, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158428 · Cited by 7
Miyaue, N., Yabe, H., & Nagai, M. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123202 · Cited by 6
YOPRO-1: A Cyanine-Based Molecular Rotor Probe for Amyloid Fibril Detection
Shahane, S. D., Mudliar, N. H., Chawda, B. R., Momin, M. M., & Singh, P. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00186 · Cited by 6
Zhang, Z., Cao, W., Xing, H., Guo, S., Huang, L., Wang, L., Sui, X. Y., Lu, K., Luo, Y., Wang, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.015 · Cited by 8
“Brain diseases seriously threaten human health, including chronic disorders ( e.g. , brain cancers 1 and neurodegenerative diseases 2 ), and acute conditions ( e.g. , cerebral infarction 3 and poisoning 4 ).”
Ou, Y., Lin, C., Fang, C.-W., & Liu, Y. (2018) · Transportation Research Part F Traffic Psychology and Behaviour · doi:10.1016/j.trf.2018.04.023 · Cited by 6
Somavarapu, A. K., Kleijwegt, G., Nagaraj, M., Alam, P., Nielsen, J., & Otzen, D. E. (2023) · Chemical Science · doi:10.1039/d2sc05534a · Cited by 7
Study of the prevalence of Parkinson's disease using dopamine transporter imaging
Kim, J., Kim, J. S., Kim, K. W., Lee, S. B., Park, J. H., Lee, J. J., Kim, Y. K., Kim, S. E., & Jeon, B. S. (2009) · Neurological Research · doi:10.1179/016164109x12581096796396 · Cited by 6
Šaponjić, J., Petrović, J., Ciric, J., & Lazic, K. (2016) · InTech eBooks · doi:10.5772/62949 · Cited by 6
The possible role of an autoimmune mechanism in the etiopathogenesis of Parkinson’s disease
Dalitis, S., Filippidou, N., Krashias, G., Christodoulou, C., Pantzaris, M., & Lambrianides, A. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.06.004 · Cited by 7
Genetics of Alzheimer's Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch43 · Cited by 6
The association between adherence and dementia in chronic obstructive pulmonary disease
Liao, K., & Chen, C. (2019) · Medicine · doi:10.1097/md.0000000000015646 · Cited by 6
“We used the presence of Alzheimer’s disease (AD) or Parkinson’s disease (PD) to represent dementia.([3]) We excluded patients with a previous diagnosis of asthma (ICD-9-CM code: 493), AD (ICD-9-CM code: 331), or PD (ICD-9-CM code: 332).”
MethodGait Model Analysis of Parkinson’s Disease Patients under Cognitive Load
Hughes, J. A., Houghten, S. K., & Brown, J. A. (2020) · IEEE Congress on Evolutionary Computation (CEC) · doi:10.1109/cec48606.2020.9185621 · Cited by 6
Targeted Therapy in Chronic Diseases Treatment by Nanomaterial Based Drug Delivery
Bhat, S., & Guddadar, V. (2021) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-799 · Cited by 6
Mathis, S., Bodduluri, S. R., & Haribabu, B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158982 · Cited by 6
Exploring role of citrus fruits in comorbid neurodegenerative disorders associated with psoriasis
Ali, A., Chaudhary, A., Sharma, A. N., Siddiqui, N., Anurag, & Parihar, V. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01479-5 · Cited by 6
Application of Neurotrophic Factors as a Therapeutic Approach for Neurodegenerative Diseases
Kim, S., Lee, S. Y., Jung, U. J., & Kim, S. R. (2025) · Experimental Neurobiology · doi:10.5607/en25023 · Cited by 5
Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review
Ratajczyk, K. J., Kaczorowska, E., Wyka, K., Tarasiuk, A., Fichna, J., & Gajos, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083531 · Cited by 5
Genetic association study between RIT2 and Parkinson’s disease in a Han Chinese population
Li, J., Zhang, J., Li, N., Wang, L., Lu, Z., Cheng, L., Sun, X., & Peng, R. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2784-6 · Cited by 5
Neuroprotective and Antiaging Essential Oils and Lipids in Plants
Das, M., & Devi, K. P. (2018) · Reference series in phytochemistry · doi:10.1007/978-3-319-54528-8_89-1 · Cited by 5
Tropea, T. F., & Chen‐Plotkin, A. S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090834 · Cited by 5
Teppang, K. L., Zhao, Q., & Yang, J. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1343118 · Cited by 5
“Of the NDs, the two most common globally are Alzheimer ’ s disease (AD) and Parkinson ’ s disease (PD) (Nussbaum and Ellis, 2003).”
BackgroundElbatrawy, A. A., Ademoye, T. A., Alnakhala, H., Tripathi, A., Plascencia‐Villa, G., Zhu, X., Perry, G. L., Dettmer, U., & Fortin, J. S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117990 · Cited by 5
Filbertone-Induced Nrf2 Activation Ameliorates Neuronal Damage via Increasing BDNF Expression
Gong, J. H., Kim, C.-S., Park, J., Kang, S., Jang, Y., Kim, M., Chung, H., Joe, Y., & Yu, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04290-x · Cited by 5
Age-Related Changes of 14-3-3 Isoforms in Midbrain of A53T-SNCA Overexpressing Mice
Brehm, N., Rau, K., Kurz, A., Gispert, S., & Auburger, G. W. J. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150606 · Cited by 6
Meléndez‐Flores, J. D., Millán-Alanís, J. M., González-Martínez, A., Álvarez‐Villalobos, N. A., & Estrada-Bellmann, I. E. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00568-5 · Cited by 5
“Clinically, it is characterized by motor symptoms such as bradykinesia, tremor, rigidity (Lee and Gilbert 2016; Nussbaum and Ellis 2003), as well as non-motor symptoms, which are reported by most patients (Lee and Gilbert 2016).”
BackgroundUnicompartmental knee arthroplasty in patients with Parkinson's disease
Goh, G. S.-H., Zeng, G. J., Thever, Y., Foong, W. S., Tay, D. K. J., Lo, N.-N., Yeo, S.-J., & Liow, M. H. L. (2020) · The Knee · doi:10.1016/j.knee.2020.06.017 · Cited by 5
Shim, Y. J., Shin, M. K., Jung, J., Koo, B., & Jang, W. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.996698 · Cited by 7
“The most frequent form of NDs is dementia, the most prevalent type of which is AD (Nussbaum and Ellis, 2003).”
BackgroundFeo, M. S. D., Frantellizzi, V., Locuratolo, N., Rocco, A. D., Farcomeni, A., Pauletti, C., Marongiu, A., Lazri, J., Nuvoli, S. M. F., Fattapposta, F., et al. (2023) · Life · doi:10.3390/life13081786 · Cited by 5
Fu, M., Li, C., Zhao, Z., Ling, K., Gong, Z., Li, H., Li, T., Li, J., Cao, W., Hu, X. Y., et al. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-04547-0 · Cited by 5
Selote, R., & Makhijani, R. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108302 · Cited by 5
Aging as a risk factor for neurodegenerative diseases: insights from Ukraine and the world
Luhovyi, O., & Bayliak, M. M. (2024) · Journal of Vasyl Stefanyk Precarpathian National University Biology · doi:10.15330/jpnubio.11.78-92 · Cited by 5
How Selegiline ((-)-Deprenyl) Slows Brain Aging
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816080547011120101 · Cited by 6
Características clínicas de las formas neurológicas de la enfermedad de Gaucher
Liesa, J. L. C., de Cabezón, A. S., Alejos, R. A., & Ara, J. R. (2011) · Medicina Clínica · doi:10.1016/s0025-7753(11)70010-0 · Cited by 5
Mind-body movement therapies for Parkinson's disease
Lee, M. S., Kim, T., Shin, B., & Ernst, E. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011266 · Cited by 5
Rendas‐Baum, R., Buck, P. O., White, M. K., & Castelli‐Haley, J. (2011) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-9-69 · Cited by 5
Xue, Z., Ji, S., Zhang, S., Mao, Z., Han, H., Yang, Q., Zhu, W., & Zhu, S. (2016) · Neurology India · doi:10.4103/0028-3886.181532 · Cited by 5
Neuroprotective Effects of Polyphenols in Aging and Age‐Related Neurological Disorders
Corona, G., & Vauzour, D. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch3 · Cited by 5
EFFECTS OF AGE, GENDER AND EDUCATION LEVEL ON COGNITION IN ELDERLY PEOPLE
Shuba, N., & Prakash, B. G. (2017) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2017/1509 · Cited by 5
Role-specific Language Models for Processing Recorded Neuropsychological Exams
Alhanai, T., Au, R., & Glass, J. R. (2018) · Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies (NAACL-HLT) · doi:10.18653/v1/n18-2117 · Cited by 5
Cabello, C., & Trandafir, P. C. (2018) · Revista Científica de la Sociedad Española de Enfermería Neurológica · doi:10.1016/j.sedene.2018.09.001 · Cited by 5
Safinamide as an adjunct therapy in older patients with Parkinson’s disease: a retrospective study
Monaco, M. R. L., Petracca, M., Vetrano, D. L., Stasio, E. D., Fusco, D., Ricciardi, D., Laudisio, A., Zuccalà, G., Onder, G., & Bentivoglio, A. R. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01469-4 · Cited by 5
An Implementation of FastAI Tabular Learner Model for Parkinson’s Disease Identification
Tandjung, M. D., Wu, J.-S., Wang, J., & Li, Y. (2021) · International Conference on Orange Technology (ICOT) · doi:10.1109/icot54518.2021.9680650 · Cited by 5
Classification of Parkinson's Disease Patients and Effectiveness of Medication for Freezing of Gait
Beigi, O. M., Nóbrega, L. R., Houghten, S. K., Andrade, A. D. O., & Pereira, A. A. (2022) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb55180.2022.9863050 · Cited by 5
Insulin signaling in the aging nervous system
Rocha, E. M., Fernandes, M. L., & Velloso, L. A. (2004) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(04)16005-7 · Cited by 5
Lee, H. J., Jeong, J. M., Rai, G., Lee, Y., Chang, Y. S., Kim, Y. J., Kim, H. W., Lee, D. S., Chung, J.-K., Mook‐Jung, I., et al. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.11.004 · Cited by 7
Inhibitors of beta-amyloid aggregation: still an issue of structure and function?
Talaga, P. E. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.05.002 · Cited by 7
Pagani, M., Salmaso, D., & Borbély, K. (2005) · PubMed · Cited by 6
Nanotechnology-based drug-delivery systems releasing growth factors to the CNS
Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42866-8.00011-3 · Cited by 10
Nonhuman Primate Models for Testing Gene Therapy for Neurodegenerative Disorders
Moirano, J. M., & Emborg, M. E. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50010-1 · Cited by 5
Zhong, Z., Nural, H. F., He, P., Civarella, G., Beach, T. G., Sue, L. I., Adler, C. H., Shill, H. A., Caviness, J. N., Xia, W., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-30 · Cited by 5
İskit, E., Aktaş, D., Özalp, L., Meletli, F., & Danış, Ö. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.03.055 · Cited by 4
Independent component analysis of oddball EEG recordings to detect Parkinson’s disease
Smrdel, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-07645-8 · Cited by 4
Ether lipids and sphingolipids drive sex-specific human aging dynamics
Sol, J., Fernàndez‐Bernal, A., Mota‐Martorell, N., Martin‐Garí, M., Òbis, È., Juanes-Casado, A., Ayala, V., Mayneris‐Perxachs, J., Ramos, R., Pineda, V., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103779 · Cited by 6
Lu, Z., Yu, X., Li, P., Wang, Y., Deng, Y., Li, X., Wang, C., & Yu, S. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1437622 · Cited by 4
“Since aging is the most important risk factor for PD (Nussbaum and Ellis, 2003; de Lau and Breteler, 2006), we also analyzed the correlation between age and RBC-o-α -Syn.”
Background(2014) · International Journal of Physical Medicine & Rehabilitation · doi:10.4172/2329-9096.1000220 · Cited by 6
Roth, A., Gärtner, F., Mayer, K., Beyrle, J., König, I., Knippschild, U., & Bischof, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126423 · Cited by 5
Yong, S. J., Veerakumarasivam, A., Teoh, S. L., Lim, W. L., & Chew, J. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02267-7 · Cited by 4
Mukaetova-Ladinska, E. B. (2011) · Future Neurology · doi:10.2217/fnl.11.7 · Cited by 4
Ben-David, E., & Tu, R. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4092 · Cited by 4
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4
Dementias and the Frontal Lobes
Harciarek, M., Sitek, E. J., & Barczak, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803676-1.00019-2 · Cited by 4
Novotni, G., Jakimovska, M., Plaseska‐Karanfilska, D., Tanovska, N., Kuzmanovski, I., Aleksovski, V., Karanfilovik, K., Baneva, N. D., Stankovic, M., Milutinovik, M., et al. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.166 · Cited by 4
“This can be considered lower in comparison to Nussbaum reports that the average age of dementia onset is around 80 years [2].”
BackgroundResultInfluentialNanobiotechnology in Parkinson’s Disease
Torres-Ortega, P. V., Martínez-Valbuena, I., Martí‐Andrés, G., Hanafy, A. S., Luquin, M. R., Garbayo, E., & Blanco‐Prieto, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_7 · Cited by 4
Ghodrati, A., Firoozpour, L., Balalaie, S., Hosseini, F. S., Ramezanpour, S., Edraki, N., Mohtavinejad, N., & Amanlou, M. (2020) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-020-10015-9 · Cited by 4
Wang, Y., Wang, Y., Zhou, M., Jiang, D.-Q., & Deng, X. (2020) · Medicine · doi:10.1097/md.0000000000023432 · Cited by 4
“3%.([1]) It is a debilitating neurological disorder characterized by resting tremor, muscular rigidity, bradykinesia, and postural instability.”
BackgroundEvaluation of Oral Manifestations of Patients with Parkinson’s Disease–An Observational Study
Gopalakrishnan, T., Mastan, K. M. K., Mouli, P. C., Guntuku, N. L., Priyadharshini, A., & Sangeetha, G. F. (2021) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v15i4.16908 · Cited by 6
Platanic acid derived amides are more cytotoxic than their corresponding oximes
Kozubek, M., Hoenke, S., Schmidt, T., Ströhl, D., & Csük, R. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02902-1 · Cited by 6
Studying the Design of Pervasive Serious Games for Parkinson’s Disease
Pinto, D., Pereira, B., Santos, P. A., & Madeira, R. N. (2022) · International Conference on Mobile and Ubiquitous Multimedia (MUM) · doi:10.1145/3568444.3570594 · Cited by 4
Parasrampuria, S., Bijelic, E., Bott, D. M., Driessen, J., Lipp, M., & Ling, S. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12953 · Cited by 6
Ince-PD Model for Parkinson’s Disease Prediction Using MDS-UPDRS I & II and PDQ-8 Score
Tsolakis, N., Maga‐Nteve, C., Μεδίτσκος, Γ., Vrochidis, S., & Kompatsiaris, I. Y. (2023) · IFIP advances in information and communication technology · doi:10.1007/978-3-031-34111-3_23 · Cited by 4
Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature
Dutta, R. (2023) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001078 · Cited by 4
Olatunji, S. O., Alzahrani, A., Alsubaie, A., Aldahlan, O., Alnafea, I., Alamri, A., Ahmed, M. I. B., Khan, M. A. A., Almuhaidib, A. S., & Alhiyafi, J. A. (2023) · International Conference on Intelligent Data Science Technologies and Applications (IDSTA) · doi:10.1109/idsta58916.2023.10317845 · Cited by 4
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.